Investors who bought Park Ha Biological Technology securities during the alleged class period from Dec. 27, 2024, through July 8, 2025, have until September 28, 2026, to seek appointment as lead plaintiff in a proposed securities class action. Pomerantz LLP alleges that Park Ha was targeted in a pump-and-dump and market-manipulation scheme involving social-media misinformation and people impersonating financial professionals. The complaint says the stock rose from its $4.00 IPO price to an all-time high of $41.49 on July 7, 2025, without material corporate developments or legitimate business prospects supporting the increase. Earlier litigation announced by The Portnoy Law Firm also alleged misleading disclosures, artificial trading activity and an unusually low public float. The announcements identify the company and ticker differently: Pomerantz lists Park Ha Biological Technology Co., Ltd. under NASDAQ: BYAH, while the earlier announcement identified Park Ha Biological Technology Co., Inc. under NASDAQ: PHH.